Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease

Completed · Phase 1 · Has a placebo group

Conditions studied: Parkinson's Disease

In brief

This multiple ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX002 in approximately 60 patients with Parkinson's disease.

Key facts

Study ID

NCT02157714

Run by

Prothena Biosciences Limited

People needed

64

Starts

2014-06-01

Last updated by the study team

2016-10-21

Who can join

Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Idiopathic Parkinson's disease, Hoehn and Yahr 1-3
• Body weight range of ≥ 45kg/99 lbs to ≤ 110 kg/242 lbs
• Female subjects must be surgically sterile or post-menopausal or if of child-bearing potential must use contraception
• Male subjects and their partners of childbearing potential must use contraception

You may not qualify if…

• Significant cardiac history
• Abnormal MRI
• Significant laboratory abnormalities

Where it is running

• Collaborative Neuroscience Network, LLC — Long Beach, California, United States
• Institute for Neurodegenerative Disorders — New Haven, Connecticut, United States
• Parkinson's Disease and Movement Disorders Center of Boca Raton — Boca Raton, Florida, United States
• MD Clinical — Hallandale, Florida, United States
• Compass Research, LLC — Orlando, Florida, United States
• QUEST Research Institute — Bingham Farms, Michigan, United States
• Oregon Health and Science University, Department of Neurology — Portland, Oregon, United States
• Baylor College of Medicine — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.